Evolus, Inc. (EOLS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:06AM EDT. Market open.
Loading interactive chart…
- Zacks
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
- Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
- GuruFocus.com
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
On May 14, 2024, David Gill, Director at Evolus Inc (NASDAQ:EOLS), executed a sale of 10,361 shares of the company.
© 2024 Yahoo. All rights reserved.